{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:08:32Z","timestamp":1778051312831,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:00:00Z","timestamp":1361232000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/leu.2013.52","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T09:02:24Z","timestamp":1361264544000},"page":"1659-1665","source":"Crossref","is-referenced-by-count":118,"title":["Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"27","author":[{"given":"A C","family":"Logan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Moorhead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M R","family":"Krampf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C D","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A N","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Faham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Zehnder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D B","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"key":"BFleu201352_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","volume":"29","author":"JG Gribben","year":"2011","unstructured":"Gribben JG, O\u2019Brien S . Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 544\u2013550.","journal-title":"J Clin Oncol"},{"key":"BFleu201352_CR2","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1182\/blood-2011-11-312421","volume":"119","author":"T Zenz","year":"2012","unstructured":"Zenz T, Gribben JG, Hallek M, Dohner H, Keating MJ, Stilgenbauer S . Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012; 119: 4101\u20134107.","journal-title":"Blood"},{"key":"BFleu201352_CR3","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446\u20135456.","journal-title":"Blood"},{"key":"BFleu201352_CR4","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956\u2013964.","journal-title":"Leukemia"},{"key":"BFleu201352_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/leu.2012.216","volume":"27","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013; 27: 142\u2013149.","journal-title":"Leukemia"},{"key":"BFleu201352_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.blre.2011.01.001","volume":"25","author":"S B\u00f6ttcher","year":"2011","unstructured":"B\u00f6ttcher S, Ritgen M, Dreger P . Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. Blood Rev 2011; 25: 91\u201396.","journal-title":"Blood Rev"},{"key":"BFleu201352_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S B\u00f6ttcher","year":"2012","unstructured":"B\u00f6ttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980\u2013988.","journal-title":"J Clin Oncol"},{"key":"BFleu201352_CR8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/sj.leu.2403478","volume":"18","author":"S B\u00f6ttcher","year":"2004","unstructured":"B\u00f6ttcher S, Ritgen M, Pott C, Bruggemann M, Raff T, Stilgenbauer S et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004; 18: 1637\u20131645.","journal-title":"Leukemia"},{"key":"BFleu201352_CR9","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/leu.2009.140","volume":"23","author":"S B\u00f6ttcher","year":"2009","unstructured":"B\u00f6ttcher S, Stilgenbauer S, Busch R, Bruggemann M, Raff T, Pott C et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009; 23: 2007\u20132017.","journal-title":"Leukemia"},{"key":"BFleu201352_CR10","doi-asserted-by":"publisher","first-page":"12ra23","DOI":"10.1126\/scitranslmed.3000540","volume":"1","author":"SD Boyd","year":"2009","unstructured":"Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 2009; 1: 12ra23.","journal-title":"Sci Transl Med"},{"key":"BFleu201352_CR11","doi-asserted-by":"publisher","first-page":"21194","DOI":"10.1073\/pnas.1118357109","volume":"108","author":"AC Logan","year":"2011","unstructured":"Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL et al. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci 2011; 108: 21194\u201321199.","journal-title":"Proc Natl Acad Sci"},{"key":"BFleu201352_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257\u20132317.","journal-title":"Leukemia"},{"key":"BFleu201352_CR13","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012; 120: 5173\u20135180.","journal-title":"Blood"},{"key":"BFleu201352_CR14","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa050642","volume":"353","author":"R Lowsky","year":"2005","unstructured":"Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA et al. Protective conditioning for acute graft-versus-host disease. New Engl J Med 2005; 353: 1321\u20131331.","journal-title":"New Engl J Med"},{"key":"BFleu201352_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2009-03-211441","volume":"114","author":"HE Kohrt","year":"2009","unstructured":"Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114: 1099\u20131109.","journal-title":"Blood"},{"key":"BFleu201352_CR16","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","volume":"119","author":"S Arai","year":"2012","unstructured":"Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012; 119: 6145\u20136154.","journal-title":"Blood"},{"key":"BFleu201352_CR17","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1182\/blood-2012-05-429811","volume":"120","author":"C Gawad","year":"2012","unstructured":"Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood 2012; 120: 4407\u20134417.","journal-title":"Blood"},{"key":"BFleu201352_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","volume":"6","author":"M Ladetto","year":"2000","unstructured":"Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241\u2013253.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu201352_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00019606-200012000-00001","volume":"9","author":"EA Ranheim","year":"2000","unstructured":"Ranheim EA, Jones CD, Zehnder JL . Sensitive detection of clonal immunoglobulin rearrangements in frozen and paraffin embedded tissues by polymerase chain reaction heteroduplex analysis. Diagn Mol Pathol 2000; 9: 177\u2013183.","journal-title":"Diagn Mol Pathol"},{"key":"BFleu201352_CR20","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone marrow transplant 1995; 15: 825\u2013828.","journal-title":"Bone marrow transplant"},{"key":"BFleu201352_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu201352_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EI Kaplan","year":"1958","unstructured":"Kaplan EI, Meier P . Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Statist Assoc"},{"key":"BFleu201352_CR23","unstructured":"Team RDC. R: a language and environment for statistical computing. In R Foundation for Statistical Computing. Vienna, Austria, 2010."},{"key":"BFleu201352_CR24","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/1097-0142(19871201)60:11<2712::AID-CNCR2820601122>3.0.CO;2-1","volume":"60","author":"S Molica","year":"1987","unstructured":"Molica S, Alberti A . Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712\u20132716.","journal-title":"Cancer"},{"key":"BFleu201352_CR25","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/sj.leu.2400801","volume":"11","author":"C Voena","year":"1997","unstructured":"Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793\u20131798.","journal-title":"Leukemia"},{"key":"BFleu201352_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/sj.leu.2403800","volume":"19","author":"P Dreger","year":"2005","unstructured":"Dreger P, Ritgen M, Bottcher S, Schmitz N, Kneba M . The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Leukemia 2005; 19: 1135\u20131138.","journal-title":"Leukemia"},{"key":"BFleu201352_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11899-009-0041-2","volume":"5","author":"AM Varghese","year":"2010","unstructured":"Varghese AM, Rawstron AC, Hillmen P . Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment? Curr Hematol Malig Rep 2010; 5: 35\u201344.","journal-title":"Curr Hematol Malig Rep"},{"key":"BFleu201352_CR28","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","volume":"116","author":"P Dreger","year":"2010","unstructured":"Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116: 2438\u20132447.","journal-title":"Blood"},{"key":"BFleu201352_CR29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3324\/haematol.2008.000273","volume":"94","author":"L Farina","year":"2009","unstructured":"Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009; 94: 654\u2013662.","journal-title":"Haematologica"},{"key":"BFleu201352_CR30","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2002-10-3270","volume":"103","author":"AC Rawstron","year":"2004","unstructured":"Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, Cullen MJ, Richards SJ et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004; 103: 2027\u20132031.","journal-title":"Blood"},{"key":"BFleu201352_CR31","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/leu.2008.96","volume":"22","author":"M Ritgen","year":"2008","unstructured":"Ritgen M, Bottcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008; 22: 1377\u20131386.","journal-title":"Leukemia"},{"key":"BFleu201352_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2141.2006.06428.x","volume":"136","author":"C Nabhan","year":"2007","unstructured":"Nabhan C, Coutre S, Hillmen P . Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol 2007; 136: 379\u2013392.","journal-title":"Br J Haematol"},{"key":"BFleu201352_CR33","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","volume":"23","author":"P Moreton","year":"2005","unstructured":"Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971\u20132979.","journal-title":"J Clin Oncol"},{"key":"BFleu201352_CR34","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","volume":"23","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819\u20133829.","journal-title":"J Clin Oncol"},{"key":"BFleu201352_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","volume":"144","author":"CD Schweighofer","year":"2009","unstructured":"Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009; 144: 95\u201398.","journal-title":"Br J Haematol"},{"key":"BFleu201352_CR36","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","volume":"107","author":"C Moreno","year":"2006","unstructured":"Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563\u20134569.","journal-title":"Blood"},{"key":"BFleu201352_CR37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation.V2012.1.88.3801172","volume":"2012","author":"A Wiestner","year":"2012","unstructured":"Wiestner A . Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 88\u201396.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu201352_CR38","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.bbmt.2010.07.001","volume":"16","author":"N Kroger","year":"2010","unstructured":"Kroger N, Bacher U, Bader P, Bottcher S, Borowitz MJ, Dreger P et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant 2010; 16: 1325\u20131346.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu201352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201352","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:04:35Z","timestamp":1684433075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,19]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFleu201352"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.52","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,19]]}}}